FDA Asks For Tough Warning On Genentech, Inc.'s (Jobs) Asthma Drug

February 21, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON (Reuters) - Genentech Inc’s asthma drug Xolair should carry the strongest warning possible about the drug’s risk of a serious reaction known as anaphylaxis, U.S. health regulators said on Wednesday.>>> Discuss This Story

Twitter
LinkedIn
Facebook
Email
Print